Skip to main content

Articles

Page 1 of 67

  1. Metastasis has been one of the primary reasons for the high mortality rates associated with tumours in recent years, rendering the treatment of current malignancies challenging and representing a significant c...

    Authors: Jiachi Jia, Yuhang Wang, Mengjia Li, Fuqi Wang, Yingnan Peng, Junhong Hu, Zhen Li, Zhilei Bian and Shuaixi Yang
    Citation: Molecular Cancer 2024 23:200
  2. Tumor cells remodel the phenotype and function of tumor microenvironment (TME) cells to favor tumor progression. Previous studies have shown that neutrophils in TME are polarized to N2 tumor-associated neutrop...

    Authors: Jiahui Zhang, Dan Yu, Cheng Ji, Maoye Wang, Min Fu, Yu Qian, Xiaoxin Zhang, Runbi Ji, Chong Li, Jianmei Gu and Xu Zhang
    Citation: Molecular Cancer 2024 23:198
  3. Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors ...

    Authors: Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind…
    Citation: Molecular Cancer 2024 23:197
  4. Colitis-associated colorectal cancer (CAC) frequently develops in patients with inflammatory bowel disease (IBD) who have been exposed to a prolonged state of chronic inflammation. The i...

    Authors: Yonger Chen, Jian Liang, Shuxian Chen, Nan Lin, Shuoxi Xu, Jindian Miao, Jing Zhang, Chen Chen, Xin Yuan, Zhuoya Xie, Enlin Zhu, Mingsheng Cai, Xiaoli Wei, Shaozhen Hou and Hailin Tang
    Citation: Molecular Cancer 2024 23:196
  5. Authors: Qing Shi, Yasheng Zhu, Jian Ma, Kun Chang, Dongling Ding, Yang Bai, Kun Gao, Pingzhao Zhang, Ren Mo, Kai Feng, Xiaying Zhao, Liang Zhang, Huiru Sun, Dongyue Jiao, Yingji Chen, Yinghao Sun…
    Citation: Molecular Cancer 2024 23:194

    The original article was published in Molecular Cancer 2019 18:170

  6. CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity of CD8+ tumour infiltrating lymphocyt...

    Authors: Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen, Lingxiao Jin, Binghao Li and Zhaoming Ye
    Citation: Molecular Cancer 2024 23:193
  7. Osteosarcoma is the most common primary bone cancer in children and young adults. Limited progress has been made in improving the survival outcomes in patients with osteosarcoma over the past four decades. Esp...

    Authors: Shengnan Yu and Xudong Yao
    Citation: Molecular Cancer 2024 23:192
  8. Cancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of e...

    Authors: Zhengjun Lin, Guoqing Li, Ke Jiang, Zhihong Li and Tang Liu
    Citation: Molecular Cancer 2024 23:191
  9. Epigenetic alterations, such as those in chromatin structure and DNA methylation, have been extensively studied in a number of tumor types. But oral cancer, particularly oral adenocarcinoma, has received far l...

    Authors: Yue Xue, Lu Liu, Ye Zhang, Yueying He, Jingyao Wang, Zicheng Ma, Tie-jun Li, Jianyun Zhang, Yanyi Huang and Yi Qin Gao
    Citation: Molecular Cancer 2024 23:190
  10. Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms o...

    Authors: Yau-Tuen Chan, Cheng Zhang, Junyu Wu, Pengde Lu, Lin Xu, Hongchao Yuan, Yibin Feng, Zhe-Sheng Chen and Ning Wang
    Citation: Molecular Cancer 2024 23:189
  11. Triple negative breast cancer (TNBC) is a particularly lethal breast cancer (BC) subtype driven by cancer stem cells (CSCs) and an immunosuppressive microenvironment. Our study reveals that nucleus accumbens a...

    Authors: Chrispus Ngule, Ruyi Shi, Xingcong Ren, Hongyan Jia, Felix Oyelami, Dong Li, Younhee Park, Jinhwan Kim, Hami Hemati, Yi Zhang, Xiaofang Xiong, Andrew Shinkle, Nathan L. Vanderford, Sara Bachert, Binhua P. Zhou, Jianlong Wang…
    Citation: Molecular Cancer 2024 23:188
  12. The plasma concentrations of acyl coenzyme A binding protein (ACBP, also known as diazepam-binding inhibitor, DBI, or ‘endozepine’) increase with age and obesity, two parameters that are also amongst the most ...

    Authors: Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, Misha Mao, Shuai Zhang, Lisa Derosa, Julie Le Naour, Flavia Lambertucci, Silvia Mingoia, Uxía Nogueira-Recalde, Rafael Mena-Osuna, Irene Herranz-Montoya, Nabil Djouder, Sylvain Baulande…
    Citation: Molecular Cancer 2024 23:187
  13. Peritumoral hepatocytes are critical components of the liver cancer microenvironment, However, the role of peritumoral hepatocytes in the local tumor immune interface and the underlying molecular mechanisms ha...

    Authors: Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou and Minshan Chen
    Citation: Molecular Cancer 2024 23:186
  14. The spatial arrangement of immune cells within the tumor microenvironment (TME) and their interactions play critical roles in the initiation and development of cancer. Several advanced technologies such as ima...

    Authors: Jian-Rong Li, Vikram Shaw, Yupei Lin, Xiang Wang, Muhammad Aminu, Yong Li, Jia Wu, Jianjun Zhang, Christopher I. Amos and Chao Cheng
    Citation: Molecular Cancer 2024 23:185
  15. Great progress has been made in utilizing immune checkpoint blockade (ICB) for the treatment of non-small-cell lung cancer (NSCLC). Therapies targeting programmed cell death protein 1 (PD-1) and its ligand PD-...

    Authors: Bo Wu, Xin Huang, Xiang Shi, Meixi Jiang, Hongxu Liu and Li Zhao
    Citation: Molecular Cancer 2024 23:184
  16. Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is constitutively expressed on various immune cel...

    Authors: Qiang Liu, Yujing Guan and Shenglong Li
    Citation: Molecular Cancer 2024 23:183

    The Correction to this article has been published in Molecular Cancer 2024 23:199

  17. The cancer genome contains several driver mutations. However, in some cases, no known drivers have been identified; these remaining areas of unmet needs, leading to limited progress in cancer therapy. Whole-ge...

    Authors: Ken Asada, Syuzo Kaneko, Ken Takasawa, Kouya Shiraishi, Norio Shinkai, Yoko Shimada, Satoshi Takahashi, Hidenori Machino, Kazuma Kobayashi, Amina Bolatkan, Masaaki Komatsu, Masayoshi Yamada, Mototaka Miyake, Hirokazu Watanabe, Akiko Tateishi, Takaaki Mizuno…
    Citation: Molecular Cancer 2024 23:182
  18. Neuroblastoma (NB) is a heterogeneous embryonal malignancy and the deadliest tumor of infancy. It is a complex disease that can result in diverse clinical outcomes. In some children, tumors regress spontaneous...

    Authors: Thale K. Olsen, Jörg Otte, Shenglin Mei, Bethel Tesfai Embaie, Polina Kameneva, Huaitao Cheng, Teng Gao, Vasilios Zachariadis, Ioanna Tsea, Åsa Björklund, Emil Kryukov, Ziyi Hou, Anna Johansson, Erik Sundström, Tommy Martinsson, Susanne Fransson…
    Citation: Molecular Cancer 2024 23:180
  19. Plenty of circRNAs have been reported to play an important role in colorectal cancer (CRC), while the reason of abnormal circRNA expression in cancer still keep elusive. Here, we found that m7G RNA modificatio...

    Authors: Zhenqiang Sun, Yanxin Xu, Chaohua Si, Xiaoke Wu, Yaxin Guo, Chen Chen and Chengzeng Wang
    Citation: Molecular Cancer 2024 23:179
  20. Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic alteration of gene express...

    Authors: Di Chen, Xinyu Gu, Yeltai Nurzat, Lixia Xu, Xueyuan Li, Lixin Wu, Henan Jiao, Peng Gao, Xuqiang Zhu, Dongming Yan, Shaohua Li and Chen Xue
    Citation: Molecular Cancer 2024 23:178
  21. The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunit...

    Authors: Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, Weixue Wang, Fan Wu, Yumin Wang and Yu Wang
    Citation: Molecular Cancer 2024 23:177
  22. Recent research has uncovered a surprisingly high occurrence of aberrant expression and mutations in the genes that encode subunits of the SWI/SNF chromatin-remodeling complexes (SCRC). Nevertheless, the carci...

    Authors: Kai Zhuang, Lishan Wang, Chengyu Lu, Zhiping Liu, Dongli Yang, Hao Zhong, Jiami Zou, Aamir Fahira, Jiaojiao Wang and Zunnan Huang
    Citation: Molecular Cancer 2024 23:176
  23. In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment effic...

    Authors: Xueting Xia, Zongxin Yang, Qisi Lu, Zhenyun Liu, Lei Wang, Jinwen Du, Yuhua Li, Dong-Hua Yang and Shaojie Wu
    Citation: Molecular Cancer 2024 23:175
  24. The drug efflux transporter P-glycoprotein, encoded by the ABCB1 gene, promotes acquired chemoresistance. We explored the presence and clinical relevance of circulating cell-free ABCB1 transcripts (cfABCB1tx) in ...

    Authors: Franziska Maria Schwarz, Jan Dominik Kuhlmann, Jorrin Kämpfer, Anna Klimova, Daniel Martin Klotz, Lisa Freitag, Pia Herrmann, Viktoria Zinnow, Janice Smith, Theresia Scheller, Wolfgang Walther, Pauline Wimberger and Ulrike Stein
    Citation: Molecular Cancer 2024 23:174
  25. Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness or subopti...

    Authors: Yibo Gao, Dandan Cao, Mengfan Li, Fuqiang Zhao, Pei Wang, Shiwen Mei, Qianqian Song, Pei Wang, Yanli Nie, Wei Zhao, Sizhen Wang, Hai Yan, Xishan Wang, Yuchen Jiao and Qian Liu
    Citation: Molecular Cancer 2024 23:173
  26. Exosomes mediate cell-to-cell crosstalk involving a variety of biomolecules through an intricate signaling network. In recent years, the pivotal role of exosomes and their non-coding RNAs cargo in the developm...

    Authors: Margherita Luongo, Pasqualina Laurenziello, Giuseppe Cesta, Anna Maria Bochicchio, Ludmila Carmen Omer, Geppino Falco, Maria Rita Milone, Francesca Cibarelli, Sabino Russi and Simona Laurino
    Citation: Molecular Cancer 2024 23:172
  27. Circular RNAs (circRNAs) are unique noncoding RNAs that have a closed and stable loop structure generated through backsplicing. Due to their conservation, stability and tissue specificity, circRNAs can potenti...

    Authors: Wenjie Zhang, Chen Xu, Zhipeng Yang, Jingshi Zhou, Wei Peng, Xuan Zhang, Haimin Li, Shibin Qu and Kaishan Tao
    Citation: Molecular Cancer 2024 23:171
  28. Gastric cancer (GC) is one of the deadliest malignant tumors with unknown pathogenesis. Due to its treatment resistance, high recurrence rate, and lack of reliable early detection techniques, a majority of pat...

    Authors: Xianzhe Yu, Yin Zhang, Fengming Luo, Qinghua Zhou and Lingling Zhu
    Citation: Molecular Cancer 2024 23:170
  29. In the KEYNOTE-811 study, anti-HER2 and immunotherapy treatments resulted in longer survival in HER2-positive gastric cancer patients with CPS ≥ 1, whereas CPS < 1 patients lacked notable benefits. We studied ...

    Authors: Yang Chen, Keren Jia, Xiaoyi Chong, Yi Xie, Lei Jiang, Haoxin Peng, Dan Liu, Jiajia Yuan, Yanyan Li, Xujiao Feng, Yu Sun, Jian Li, Xiaotian Zhang and Lin Shen
    Citation: Molecular Cancer 2024 23:169
  30. Information transmission between primary tumor cells and immunocytes or stromal cells in distal organs is a critical factor in the formation of pre-metastatic niche (PMN). Understanding this mechanism is essen...

    Authors: Jing Zhou, Qing Song, Haoze Li, Yicun Han, Yunzhou Pu, Ling Li, Wenqing Rong, Xiaodie Liu, Ziyuan Wang, Jian Sun, Yuqing Song, Xueyan Hu, Guanghao Zhu, Huirong Zhu, Liu Yang, Guangbo Ge…
    Citation: Molecular Cancer 2024 23:168
  31. Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many pati...

    Authors: Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou…
    Citation: Molecular Cancer 2024 23:166
  32. The Phosphatidylinositol-3-kinase (PI3K) family is well-known to comprise three classes of intracellular enzymes. Class I PI3Ks primarily function in signaling by responding to cell surface receptor stimulatio...

    Authors: Hongyao Li, Xiang Wen, Yueting Ren, Zhichao Fan, Jin Zhang, Gu He and Leilei Fu
    Citation: Molecular Cancer 2024 23:164
  33. Platinum-resistant or refractory ovarian cancer is a highly lethal gynecologic disease with limited treatment options. Chiauranib is a novel small-molecule selective inhibitor, which could effectively target m...

    Authors: Jin Li, Jihong Liu, Rutie Yin, Dongling Zou, Hong Zheng, Junning Cao, Zhendong Chen, Wei Sun, Yunong Gao, Songling Zhang, Linjuan Zeng, Ruifang An, Xianping Lu, Shuang Ye and Xiaohua Wu
    Citation: Molecular Cancer 2024 23:162
  34. Identifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In ...

    Authors: Annamaria Salvati, Giorgio Giurato, Jessica Lamberti, Ilaria Terenzi, Laura Crescenzo, Viola Melone, Luigi Palo, Alessandro Giordano, Francesco Sabbatino, Giuseppina Roscigno, Cristina Quintavalle, Gerolama Condorelli, Francesca Rizzo, Roberta Tarallo, Giovanni Nassa and Alessandro Weisz
    Citation: Molecular Cancer 2024 23:160
  35. Circular RNA (circRNA) is thought to mediate the occurrence and development of human cancer and usually acts as a tiny RNA (miRNA) sponge to regulate downstream gene expression. However, it is not clear whethe...

    Authors: Du Fei, Fang Wang, Yaohui Wang, Ji Chen, Shendong Chen, Lianpeng Fan, Luhan Yang, Qingyi Ren, Suwit Duangmano, Fukuan Du, Hao Liu, Jie Zhou, Jing Sheng, Yueshui Zhao, Xu Wu, Mingxing Li…
    Citation: Molecular Cancer 2024 23:159
  36. PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PA...

    Authors: Ksenija Nesic, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya Kwan, Elizabeth Lieschke, Gwo-Yaw Ho, Holly E. Barker, Justin Bedo, Silvia Casadei, Andrew Farrell, Marc Radke, Kristy Shield-Artin, Jocelyn S. Penington…
    Citation: Molecular Cancer 2024 23:158
  37. Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis. The heterogeneity of hepatocellular carcinoma (HCC) in cellular level is not clear.

    Authors: De-Zhen Guo, Xin Zhang, Sen-Quan Zhang, Shi-Yu Zhang, Xiang-Yu Zhang, Jia-Yan Yan, San-Yuan Dong, Kai Zhu, Xin-Rong Yang, Jia Fan, Jian Zhou and Ao Huang
    Citation: Molecular Cancer 2024 23:157
  38. Elevated microRNA-155 (miR-155) expression in non-small-cell lung cancer (NSCLC) promotes cisplatin resistance and negatively impacts treatment outcomes. However, miR-155 can also boost anti-tumor immunity by ...

    Authors: Prashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, Joseph Cave, Joseph D. Butner, Carmine Schiavone, Dan G. Duda, Ahmed O. Kaseb, Caroline Chung, Eugene J. Koay, Vittorio Cristini, Bulent Ozpolat, George A. Calin and Zhihui Wang
    Citation: Molecular Cancer 2024 23:156
  39. Immune checkpoint therapy (ICT) provides durable responses in select cancer patients, yet resistance remains a significant challenge, prompting the exploration of underlying molecular mechanisms. Tyrosylprotei...

    Authors: Yumi Oh, Sujeong Kim, Yunjae Kim, Hyun Kim, Dongjun Jang, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee, Jaeik Oh, Yoojin Yang, Dohee Kim, Hae Rim Jung, Sangjin Kim, Jihui Kim, Kyungchan Min…
    Citation: Molecular Cancer 2024 23:155
  40. Cancer is the second leading cause of death worldwide and disease burden is expected to increase globally throughout the next several decades, with the majority of cancer-related deaths occurring in metastatic...

    Authors: Saurav Kiri and Tyrone Ryba
    Citation: Molecular Cancer 2024 23:154
  41. The hallmarks of stem cells, such as proliferation, self-renewal, development, differentiation, and regeneration, are critical to maintain stem cell identity which is sustained by genetic and epigenetic factor...

    Authors: Hongying Ma, Jian Qu, Zicheng Pang, Jian Luo, Min Yan, Weixin Xu, Haihui Zhuang, Linxin Liu and Qiang Qu
    Citation: Molecular Cancer 2024 23:153
  42. Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibito...

    Authors: Hong-Xiang Shi, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Li-Li Hou, Hua Sun, Chang-Jiang Qin, Dong Fang and Song-Qiang Xie
    Citation: Molecular Cancer 2024 23:152

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 27.7
    5-year Journal Impact Factor: 31.3
    Source Normalized Impact per Paper (SNIP): 4.737
    SCImago Journal Rank (SJR): 8.222

    Speed 2023
    Submission to first editorial decision (median days): 3
    Submission to acceptance (median days): 91

    Usage 2023
    Downloads: 3,569,666
    Altmetric mentions: 2,070